Abstract
Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
H M Beere, C M Chresta and J A Hickman
Molecular Pharmacology May 1996, 49 (5) 842-851;